SVRA Savara Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1160308 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.1%
TTM EPS YoY-13.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-151.0%
ROA-102.9%
ROIC (approx.)-114.7%
Asset turnover—
Leverage & solvency
Liabilities / assets30.8%
Debt / equity0.28x
Current ratio8.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-15.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $24.95M | $21.95M | $23.40M | $20.90M | $20.59M | $20.75M | $19.16M | $23.29M |
| SG&A expense | $18.54M | $18.99M | $15.57M | $12.53M | $9.63M | $10.65M | $9.25M | $7.85M |
| Operating income | -$43.54M | -$40.97M | -$38.99M | -$33.42M | -$30.25M | -$31.44M | -$28.43M | -$31.17M |
| Pretax income | — | — | — | — | — | — | -$26.64M | — |
| Net income | -$42.99M | -$40.23M | -$37.28M | -$32.24M | -$29.56M | -$30.40M | -$26.64M | -$29.04M |
| EBITDA | -$43.49M | -$40.94M | -$38.97M | -$33.43M | -$30.22M | -$31.41M | -$28.41M | -$31.14M |
| EPS (basic) | -0.17 | -0.16 | -0.15 | — | -0.14 | -0.14 | -0.12 | — |
| EPS (diluted) | -0.17 | -0.16 | -0.15 | — | -0.14 | -0.14 | -0.12 | — |
| Weighted avg. shares (diluted) | 254.22M | 253.57M | 253.28M | — | 216.46M | 216.43M | 216.15M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $29.81M | $41.80M | $38.79M | $33.18M | $16.28M | $17.44M | $19.56M | $15.13M |
| Short-term investments | $99.84M | $131.23M | $163.98M | $202.52M | $108.11M | $129.01M | $152.94M | $181.20M |
| Current assets | $142.12M | $178.32M | $209.26M | $241.62M | $128.20M | $150.99M | $177.44M | $202.13M |
| PP&E, net | $716,000 | $641,000 | $130,000 | $100,000 | $85,000 | $119,000 | $138,000 | $165,000 |
| Total assets | $155.93M | $192.14M | $221.65M | $253.44M | $140.92M | $163.76M | $189.32M | $212.88M |
| Current liabilities | $16.63M | $17.60M | $15.54M | $20.40M | $16.76M | $13.63M | $11.90M | $14.72M |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term debt | $30.24M | $30.11M | $30.07M | $29.91M | $29.78M | $29.65M | $29.52M | $26.62M |
| Total debt | $30.24M | $30.11M | $30.07M | $29.91M | $29.78M | $29.65M | $29.52M | $26.62M |
| Total liabilities | $48.08M | $48.48M | $45.61M | $50.30M | $46.54M | $43.28M | $41.47M | $41.43M |
| Shareholders' equity | $107.85M | $143.66M | $176.04M | $203.13M | $94.39M | $120.48M | $147.85M | $171.45M |
| Net debt | $430,000 | -$11.69M | -$8.72M | -$3.27M | $13.50M | $12.22M | $9.97M | $11.49M |
| Shares outstanding | 205.54M | 205.40M | 204.92M | 204.57M | — | 172.85M | 172.70M | 172.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$42.46M | -$29.75M | -$33.05M | -$25.06M | -$22.53M | -$26.26M | -$27.19M | -$23.28M |
| Capital expenditure | $353,000 | $222,000 | $54,000 | $2,000 | $2,000 | $15,000 | $3,000 | -$9,000 |
| Free cash flow | -$42.82M | -$29.97M | -$33.10M | -$25.06M | -$22.53M | -$26.28M | -$27.19M | -$23.27M |
| Investing cash flow | $31.01M | $32.60M | $38.78M | -$93.56M | $21.47M | $24.33M | $29.33M | $17.89M |
| Financing cash flow | -$385,000 | $189,000 | -$195,000 | $135.56M | -$23,000 | -$49,000 | $2.32M | -$843,000 |
| Depreciation & amortization | $56,000 | $28,000 | $24,000 | -$11,000 | $36,000 | $34,000 | $30,000 | $32,000 |
| Stock-based compensation | $7.83M | $7.76M | $10.73M | $5.36M | $3.42M | $2.67M | $2.97M | $3.04M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.